唑来膦酸联合鲑降钙素治疗重度恶性高钙血症21例

The Clinical Effects of Zoledronate and Salmon Calcitonin for Severe Hypercalcemia in 21 Patients with Malignant Tumor

目的 探讨唑来膦酸联合鲑降钙素治疗重度恶性高钙血症的疗效及安全性.方法 回顾性分析2013年7月—2016年6月收治的21例恶性高钙血症危象患者,均采用唑来膦酸联合鲑降钙素治疗,同时给予补液、利尿和补充白蛋白等支持治疗,观察其疗效和不良反应.结果 21例患者治疗前血钙水平为（4.06±0.50）mmol/L,治疗后3 d血钙水平下降至（2.89±0.67）mmol/L,治疗7 d后血钙水平下降至（2.20±0.38）mmol/L,18例患者在治疗7 d时血钙水平下降至正常,3例患者经上述措施仍控制不佳行血液透析治疗后好转,上述治疗耐受性良好、未见严重不良反应.结论 唑来膦酸联合鲑降钙素治疗重度恶性高钙血症近期疗效满意,不良反应轻.

Objective To explore the clinical effects of zoledronate and salmon calcitonic of severe hypercalcemia in 21 patients with malignant tumor. Methods The 21 patients with cancer-induced hypercalcemia received zoledronate, salmon calcitonic, fluid therapy, diuresis and albumin infusion, and then was evaluated the clinical effects and adverse effects. Results The serum calcium level was （4.06±0.50） mmol/L before treatment, （2.89±0.67） mmol/L after treatment for 3 days, and （2.20±0.38） mmol/L after treatment for 7 days. The blood calcium concentration of 18 patients reached normal level after treatments for 7 days, of 3 patients reached normal level after hemodialysis. The treatment was well tolerated and has no severe adverse effects. Conclusion The combination of zoledronate and salmon calcitonic is an effective and safe treatment for patients with malignant tumor induced hypercalcemia.